肺腺癌卵巢转移在临床上很少发现，仅有少数病例报道。其临床病理特征、分子遗传学和预后尚未得到很好的表征。对2013年至2022年间诊断患有该病的17例患者的数据进行回顾性分析。所有患者均不吸烟，中位年龄为 46 岁（范围 30-71 岁）。单侧卵巢受累比双侧卵巢受累更常见（58.8% vs 41.2%）。病变表现为卵巢实性或囊实性混合肿块，近三分之二的肿瘤（11/17，64.7%）直径大于10 cm。实体腺癌是最常见的组织学亚型（9/17，52.9%），其中3例显示丰富的细胞内粘蛋白和印戒细胞。腺泡腺癌是第二常见的类型（6/17，35.3%），通常为中度至低分化。其余两例被鉴定为微乳头状腺癌和粘液性腺癌。半数病例可见多结节生长、坏死和淋巴管侵犯，其中大多数有明显的间质反应。最常见的分子改变是 ALK 重排（8/17，47.1%），其次是 EGFR 基因突变（5/17，29.4%）。生存分析共纳入 34 例病例，其中 17 例来自队列，17 例来自文献。具有 ALK 重排基因的患者表现出 80.0% 的 2 年总生存率，而那些没有 ALK 重排的患者表现出较低的 33.7%。尽管 ALK 重排基因患者的预后似乎可能更好，但需要更多病例和延长随访时间来证实这一观察结果。版权所有 © 2024 澳大利亚皇家病理学家学院。由 Elsevier B.V. 出版。保留所有权利。

Lung adenocarcinoma metastatic to the ovary is rarely detected in clinical practice, and only a few cases have been reported. Its clinicopathological features, molecular genetics, and prognosis have not been well characterised. The data of 17 patients diagnosed with this disease between 2013 and 2022 were analysed retrospectively. All patients were non-smokers, with a median age of 46 years (range 30-71 years). Unilateral ovarian involvement was more frequent than bilateral involvement (58.8% vs 41.2%). Lesions presented as solid ovarian or mixed cystic and solid masses, and nearly two-thirds of the tumours (11/17, 64.7%) had a diameter greater than 10 cm. Solid adenocarcinoma was the most common histological subtype (9/17, 52.9%), and three of the cases showed abundant intracellular mucin and signet ring cells. Acinar adenocarcinoma was the second most common type (6/17, 35.3%), usually of moderate to poor differentiation. The remaining two cases were identified as micropapillary adenocarcinoma and mucinous adenocarcinoma. Multinodular growth, necrosis, and lymphovascular invasion were observed in half of the cases, and most of them had a marked stromal response. The most prevalent molecular alteration was ALK-rearranged (8/17, 47.1%), followed by EGFR gene mutations (5/17, 29.4%). A total of 34 cases, comprising 17 from the cohort and 17 from the literature, were included in the survival analysis. Patients with ALK-rearranged genes demonstrated an 80.0% 2-year overall survival rate, whereas those without ALK rearrangement exhibited a lower rate of 33.7%. Although there appears to be a potentially better prognosis for patients with ALK-rearranged genes, further cases and an extended follow-up period are necessary to substantiate this observation.Copyright © 2024 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.